Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abortion, Induced | 10 | 2025 | 149 | 5.700 |
Why?
|
| Pregnancy | 53 | 2025 | 3113 | 4.640 |
Why?
|
| Opioid-Related Disorders | 7 | 2023 | 202 | 3.430 |
Why?
|
| Hypertension, Pregnancy-Induced | 6 | 2024 | 84 | 2.780 |
Why?
|
| Meningomyelocele | 4 | 2025 | 25 | 2.780 |
Why?
|
| Labor, Induced | 5 | 2024 | 31 | 2.560 |
Why?
|
| Premature Birth | 5 | 2024 | 124 | 2.440 |
Why?
|
| Pre-Eclampsia | 7 | 2024 | 261 | 2.380 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2024 | 122 | 2.290 |
Why?
|
| Pregnancy Outcome | 5 | 2024 | 265 | 2.120 |
Why?
|
| HIV Infections | 7 | 2024 | 896 | 2.060 |
Why?
|
| Pregnancy Complications | 7 | 2024 | 346 | 2.030 |
Why?
|
| Buprenorphine | 3 | 2022 | 43 | 1.990 |
Why?
|
| Cesarean Section | 4 | 2025 | 148 | 1.930 |
Why?
|
| Placenta Accreta | 2 | 2024 | 10 | 1.790 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2024 | 71 | 1.740 |
Why?
|
| Methadone | 4 | 2022 | 48 | 1.700 |
Why?
|
| Obstetrics | 3 | 2024 | 123 | 1.550 |
Why?
|
| Female | 56 | 2025 | 47905 | 1.520 |
Why?
|
| Cost-Benefit Analysis | 6 | 2024 | 488 | 1.490 |
Why?
|
| Opiate Substitution Treatment | 4 | 2022 | 43 | 1.460 |
Why?
|
| Postpartum Period | 6 | 2025 | 159 | 1.420 |
Why?
|
| Reproductive Health | 3 | 2017 | 36 | 1.370 |
Why?
|
| Gestational Age | 6 | 2024 | 327 | 1.350 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2023 | 247 | 1.320 |
Why?
|
| Prenatal Care | 5 | 2024 | 82 | 1.310 |
Why?
|
| Hypertension | 4 | 2024 | 763 | 1.200 |
Why?
|
| Humans | 64 | 2025 | 92351 | 1.150 |
Why?
|
| Pregnancy, Twin | 2 | 2024 | 8 | 1.110 |
Why?
|
| Hysterectomy | 2 | 2024 | 161 | 1.020 |
Why?
|
| Gynecology | 3 | 2024 | 129 | 1.000 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 329 | 0.930 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 315 | 0.930 |
Why?
|
| Delivery, Obstetric | 4 | 2024 | 120 | 0.910 |
Why?
|
| Conservative Treatment | 1 | 2024 | 24 | 0.900 |
Why?
|
| Travel | 1 | 2025 | 72 | 0.880 |
Why?
|
| Fetal Growth Retardation | 1 | 2024 | 68 | 0.880 |
Why?
|
| Misoprostol | 1 | 2024 | 17 | 0.880 |
Why?
|
| Pandemics | 2 | 2020 | 807 | 0.870 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2024 | 14 | 0.850 |
Why?
|
| Intimate Partner Violence | 1 | 2024 | 28 | 0.840 |
Why?
|
| Contraception Behavior | 1 | 2024 | 28 | 0.830 |
Why?
|
| Adult | 25 | 2025 | 27551 | 0.820 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 119 | 0.810 |
Why?
|
| Fetofetal Transfusion | 1 | 2022 | 8 | 0.800 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 452 | 0.780 |
Why?
|
| Labor Pain | 1 | 2022 | 6 | 0.780 |
Why?
|
| Residence Characteristics | 1 | 2024 | 203 | 0.770 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 130 | 0.770 |
Why?
|
| Retrospective Studies | 12 | 2025 | 9694 | 0.760 |
Why?
|
| Racism | 3 | 2019 | 96 | 0.760 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 276 | 0.750 |
Why?
|
| Infant, Newborn | 8 | 2024 | 2506 | 0.750 |
Why?
|
| Substance-Related Disorders | 4 | 2020 | 424 | 0.710 |
Why?
|
| Young Adult | 11 | 2024 | 6623 | 0.710 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 153 | 0.700 |
Why?
|
| Refugees | 2 | 2022 | 6 | 0.690 |
Why?
|
| Patient Rights | 1 | 2020 | 16 | 0.680 |
Why?
|
| Viremia | 1 | 2020 | 49 | 0.680 |
Why?
|
| Contraindications, Drug | 1 | 2020 | 3 | 0.680 |
Why?
|
| Perinatal Care | 1 | 2020 | 21 | 0.680 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2023 | 164 | 0.670 |
Why?
|
| Cefazolin | 1 | 2020 | 7 | 0.670 |
Why?
|
| Home Childbirth | 1 | 2020 | 2 | 0.670 |
Why?
|
| Pregnancy, High-Risk | 1 | 2020 | 16 | 0.670 |
Why?
|
| Cerclage, Cervical | 1 | 2020 | 5 | 0.670 |
Why?
|
| Labor, Obstetric | 1 | 2020 | 46 | 0.670 |
Why?
|
| Indomethacin | 1 | 2020 | 59 | 0.670 |
Why?
|
| Coronavirus | 1 | 2020 | 18 | 0.660 |
Why?
|
| Mothers | 1 | 2021 | 149 | 0.660 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 44 | 0.660 |
Why?
|
| Prisoners | 1 | 2020 | 46 | 0.650 |
Why?
|
| Fetus | 2 | 2023 | 234 | 0.650 |
Why?
|
| Acculturation | 1 | 2020 | 15 | 0.650 |
Why?
|
| Poverty | 1 | 2021 | 189 | 0.640 |
Why?
|
| Obstetric Labor, Premature | 1 | 2020 | 58 | 0.640 |
Why?
|
| Child Development | 1 | 2021 | 168 | 0.630 |
Why?
|
| Watchful Waiting | 4 | 2024 | 69 | 0.630 |
Why?
|
| Mass Screening | 1 | 2024 | 675 | 0.610 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 658 | 0.600 |
Why?
|
| Illinois | 3 | 2025 | 502 | 0.550 |
Why?
|
| Violence | 2 | 2017 | 147 | 0.540 |
Why?
|
| Siblings | 1 | 2017 | 108 | 0.540 |
Why?
|
| Decision Support Techniques | 3 | 2024 | 175 | 0.540 |
Why?
|
| Music | 1 | 2017 | 33 | 0.520 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 173 | 0.520 |
Why?
|
| Police | 1 | 2017 | 25 | 0.510 |
Why?
|
| Internship and Residency | 2 | 2024 | 1087 | 0.510 |
Why?
|
| Blood Pressure | 1 | 2020 | 906 | 0.500 |
Why?
|
| Bioethical Issues | 1 | 2016 | 38 | 0.500 |
Why?
|
| Altruism | 1 | 2016 | 34 | 0.490 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2016 | 110 | 0.490 |
Why?
|
| Personal Autonomy | 1 | 2016 | 117 | 0.480 |
Why?
|
| Minority Groups | 1 | 2017 | 152 | 0.480 |
Why?
|
| Cohort Studies | 4 | 2024 | 2980 | 0.480 |
Why?
|
| United States | 8 | 2024 | 7369 | 0.470 |
Why?
|
| Physicians | 1 | 2022 | 694 | 0.460 |
Why?
|
| Peripartum Period | 3 | 2024 | 29 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 808 | 0.450 |
Why?
|
| Chorioamnionitis | 2 | 2024 | 21 | 0.430 |
Why?
|
| Global Health | 1 | 2016 | 199 | 0.430 |
Why?
|
| Fetoscopy | 2 | 2024 | 9 | 0.430 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 153 | 0.430 |
Why?
|
| Consumer Advocacy | 1 | 2013 | 10 | 0.410 |
Why?
|
| Laser Coagulation | 2 | 2024 | 56 | 0.410 |
Why?
|
| Healthcare Disparities | 4 | 2024 | 443 | 0.390 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2024 | 82 | 0.390 |
Why?
|
| Poverty Areas | 1 | 2012 | 37 | 0.380 |
Why?
|
| Population Density | 1 | 2012 | 63 | 0.380 |
Why?
|
| Analgesics, Opioid | 3 | 2022 | 470 | 0.380 |
Why?
|
| Politics | 1 | 2012 | 51 | 0.380 |
Why?
|
| Reproductive Rights | 2 | 2024 | 2 | 0.380 |
Why?
|
| Physician's Role | 1 | 2013 | 179 | 0.360 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 183 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 886 | 0.330 |
Why?
|
| Logistic Models | 3 | 2020 | 1239 | 0.330 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2020 | 45 | 0.330 |
Why?
|
| Anthropology, Medical | 2 | 2022 | 2 | 0.320 |
Why?
|
| Qualitative Research | 4 | 2024 | 326 | 0.320 |
Why?
|
| Narcotic Antagonists | 2 | 2022 | 165 | 0.320 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 414 | 0.310 |
Why?
|
| Length of Stay | 2 | 2024 | 790 | 0.300 |
Why?
|
| San Francisco | 2 | 2020 | 25 | 0.290 |
Why?
|
| Social Justice | 2 | 2019 | 55 | 0.270 |
Why?
|
| Linear Models | 2 | 2020 | 427 | 0.270 |
Why?
|
| California | 2 | 2018 | 156 | 0.270 |
Why?
|
| Prospective Studies | 4 | 2024 | 4474 | 0.260 |
Why?
|
| Parity | 2 | 2024 | 97 | 0.260 |
Why?
|
| Child | 3 | 2023 | 7311 | 0.250 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 995 | 0.240 |
Why?
|
| Time Factors | 2 | 2024 | 5429 | 0.230 |
Why?
|
| Health Policy | 2 | 2016 | 190 | 0.230 |
Why?
|
| Twins, Monozygotic | 1 | 2024 | 58 | 0.220 |
Why?
|
| Uterine Rupture | 1 | 2024 | 7 | 0.220 |
Why?
|
| Lebanon | 2 | 2016 | 3 | 0.220 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2024 | 11 | 0.220 |
Why?
|
| Laminaria | 1 | 2023 | 4 | 0.220 |
Why?
|
| Placenta Growth Factor | 1 | 2024 | 75 | 0.210 |
Why?
|
| Patient Discharge | 2 | 2024 | 340 | 0.210 |
Why?
|
| Abdominal Pain | 1 | 2025 | 144 | 0.210 |
Why?
|
| Dilatation | 1 | 2023 | 47 | 0.210 |
Why?
|
| Eligibility Determination | 1 | 2023 | 36 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 99 | 0.200 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2023 | 62 | 0.200 |
Why?
|
| Oxytocin | 1 | 2023 | 74 | 0.200 |
Why?
|
| Infant | 2 | 2021 | 3206 | 0.200 |
Why?
|
| Contraception | 1 | 2024 | 99 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2024 | 134 | 0.190 |
Why?
|
| Lasers | 1 | 2022 | 107 | 0.190 |
Why?
|
| Naloxone | 1 | 2022 | 69 | 0.190 |
Why?
|
| Adolescent | 3 | 2020 | 9492 | 0.190 |
Why?
|
| Abortion, Legal | 1 | 2022 | 29 | 0.190 |
Why?
|
| Conscience | 1 | 2022 | 20 | 0.190 |
Why?
|
| Aftercare | 1 | 2023 | 88 | 0.190 |
Why?
|
| Pregnancy Trimester, First | 1 | 2022 | 63 | 0.190 |
Why?
|
| Heroin | 1 | 2022 | 12 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 102 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 86 | 0.190 |
Why?
|
| Wechsler Scales | 1 | 2021 | 21 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2024 | 354 | 0.180 |
Why?
|
| Risk | 2 | 2022 | 661 | 0.180 |
Why?
|
| Risk Factors | 2 | 2023 | 5705 | 0.180 |
Why?
|
| Wireless Technology | 1 | 2021 | 21 | 0.180 |
Why?
|
| Family | 1 | 2023 | 324 | 0.180 |
Why?
|
| Obesity, Morbid | 1 | 2024 | 242 | 0.170 |
Why?
|
| Gender Dysphoria | 1 | 2021 | 10 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 31 | 0.170 |
Why?
|
| Informed Consent | 2 | 2023 | 278 | 0.170 |
Why?
|
| Pregnant Women | 1 | 2020 | 39 | 0.170 |
Why?
|
| Hospitals | 1 | 2023 | 313 | 0.170 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2020 | 4 | 0.170 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 55 | 0.170 |
Why?
|
| Self Report | 1 | 2022 | 307 | 0.170 |
Why?
|
| Cervix Uteri | 1 | 2020 | 72 | 0.160 |
Why?
|
| Sterilization, Involuntary | 1 | 2019 | 1 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 268 | 0.160 |
Why?
|
| Physical Examination | 1 | 2020 | 151 | 0.160 |
Why?
|
| Viral Load | 1 | 2020 | 147 | 0.150 |
Why?
|
| Chicago | 1 | 2024 | 1463 | 0.150 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 147 | 0.150 |
Why?
|
| Transgender Persons | 1 | 2021 | 118 | 0.150 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2733 | 0.150 |
Why?
|
| Birth Rate | 1 | 2018 | 12 | 0.150 |
Why?
|
| Counseling | 1 | 2020 | 171 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 863 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2024 | 798 | 0.140 |
Why?
|
| Patient Safety | 1 | 2020 | 220 | 0.140 |
Why?
|
| Decision Making | 1 | 2023 | 680 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 270 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2022 | 630 | 0.130 |
Why?
|
| Semantics | 1 | 2017 | 49 | 0.130 |
Why?
|
| Social Marginalization | 1 | 2017 | 3 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 805 | 0.130 |
Why?
|
| Law Enforcement | 1 | 2017 | 10 | 0.130 |
Why?
|
| Homicide | 1 | 2017 | 49 | 0.130 |
Why?
|
| Family Planning Services | 1 | 2017 | 43 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2024 | 2368 | 0.130 |
Why?
|
| Maternal Age | 1 | 2016 | 45 | 0.130 |
Why?
|
| Comorbidity | 1 | 2020 | 986 | 0.130 |
Why?
|
| Pregnancy in Diabetics | 1 | 2016 | 39 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1117 | 0.130 |
Why?
|
| Syria | 1 | 2016 | 2 | 0.120 |
Why?
|
| Male | 5 | 2024 | 43928 | 0.120 |
Why?
|
| Arabs | 1 | 2016 | 16 | 0.120 |
Why?
|
| Unemployment | 1 | 2016 | 11 | 0.120 |
Why?
|
| Algorithms | 1 | 2024 | 1961 | 0.120 |
Why?
|
| Morals | 1 | 2017 | 97 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 224 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2016 | 172 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2016 | 694 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2017 | 200 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2021 | 3806 | 0.110 |
Why?
|
| Treatment Refusal | 2 | 2024 | 62 | 0.110 |
Why?
|
| Ethics, Medical | 1 | 2016 | 308 | 0.110 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 437 | 0.100 |
Why?
|
| Smoking | 1 | 2016 | 639 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 173 | 0.090 |
Why?
|
| Surgical Wound Infection | 2 | 2024 | 225 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2024 | 448 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2012 | 497 | 0.080 |
Why?
|
| Middle Aged | 3 | 2024 | 27050 | 0.080 |
Why?
|
| Fetal Distress | 1 | 2025 | 11 | 0.060 |
Why?
|
| Uterine Hemorrhage | 1 | 2024 | 21 | 0.060 |
Why?
|
| Organ Size | 1 | 2024 | 374 | 0.050 |
Why?
|
| Uterus | 1 | 2024 | 222 | 0.050 |
Why?
|
| Refusal to Treat | 1 | 2022 | 27 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 41 | 0.050 |
Why?
|
| Focus Groups | 1 | 2022 | 186 | 0.050 |
Why?
|
| Women's Health | 1 | 2022 | 105 | 0.050 |
Why?
|
| Heart Rate, Fetal | 1 | 2021 | 16 | 0.040 |
Why?
|
| Uterine Contraction | 1 | 2021 | 8 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2022 | 159 | 0.040 |
Why?
|
| Vital Signs | 1 | 2021 | 36 | 0.040 |
Why?
|
| Gender Identity | 1 | 2021 | 55 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 1593 | 0.040 |
Why?
|
| Health Resources | 1 | 2021 | 80 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 955 | 0.040 |
Why?
|
| Placenta | 1 | 2022 | 187 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 474 | 0.040 |
Why?
|
| Czechoslovakia | 1 | 2019 | 2 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2022 | 390 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1771 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 926 | 0.040 |
Why?
|
| Biomarkers | 1 | 2024 | 1847 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 223 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1006 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 8729 | 0.010 |
Why?
|